Prescribe PAXLOVID^
A GUIDE TO PRESCRIBING COVID-19 ORAL ANTIVIRALS FOR PBS-ELIGIBLE PATIENTS
This flowchart has been developed based on the Product Information and PBS eligibility criteria . It has been provided as guidance to help you in prescribing COVID-19 oral antivirals .
YES
Is the patient taking other medication ( including OTC medication and herbal products )?
NO
Check for potential interactions between PAXLOVID and the patient ’ s concomitant medication
Interactions can be checked using the University of Liverpool COVID-19 Drug Interactions Checker † or PAXLOVID Product Information . 1 , 4 , 5
Can drug interactions between PAXLOVID and the patient ’ s concomitant medication be managed ?
NO
YES
Does the patient have severe renal and / or severe hepatic impairment ?
Consider prescribing an alternative COVID-19 oral antiviral 3 , 4
YES
NO
Document details / reasons of contraindications to PAXLOVID in the patient ’ s medical records 3
Prescribe PAXLOVID^
Dose adjustment is recommended for patients with moderate renal impairment ( eGFR ≥30 to < 60 mL / min / 1.73m 2 ). 1 Scan the QR code for PAXLOVID dosage guidance .
^If clinically appropriate
†
Liverpool COVID-19 Drug Interactions Checker disclaimers :
1 . Pfi zer was not involved in the development of the Liverpool Drug Interactions Checker , and the information contained in the Liverpool Drug Interactions Checker is neither owned nor controlled by Pfi zer . 2 . Pfi zer accepts no responsibility for the content or services of the Liverpool Drug Interactions Checker , and excludes all warranties , express or implied , in connection with the use of the Liverpool Drug Interactions Checker , as well as all liability ( including for negligence ) for any personal injury or death , or loss , expense or damage ( including loss of opportunity ) whether direct , indirect , special or consequential , arising in any way out of or in connection with the use of the Liverpool Drug Interactions Checker . 3 . Advice contained within the Liverpool Drug Interactions Checker may not be fully consistent with the Product Information of drugs registered in Australia , and Pfi zer makes no representations and gives no warranties as to the accuracy or currency of the information contained in the Liverpool Drug Interactions Tracker . 4 . If a drug is not listed in the Liverpool Drug Interactions Checker , it should not be assumed it is safe for co-administration . 5 . Refer to the Product Information ( PI ) of each medication taken by a patient prior to prescribing and dispensing an antiviral therapy , as well as the PI of the antiviral to be prescribed .
Abbreviations : AE : adverse event ; eGFR : estimated glomerular fi ltration rate ; OTC : over-the-counter ; PBS : Pharmaceutical Benefi ts Scheme .
References : 1 . PAXLOVID ® Product Information . 2 . Pharmaceutical Benefi ts Scheme . Nirmatrelvir & Ritonavir . Available at : https :// www . pbs . gov . au / medicine / item / 12996B-13147Y . Accessed March 2024 . 3 . Pharmaceutical Benefi ts Scheme . Lagevrio ® ( molnupiravir ) Factsheet – Updated December 2024 . Available at : https :// www . pbs . gov . au / publication / factsheets / covid-19-treatments / PBS-Factsheet-lagevrio-molnupiravir-updated-December-2024 . pdf . Accessed January 2025 . 4 . Pharmaceutical Benefi ts Scheme . PAXLOVID ® ( nirmatrelvir and ritonavir ) Factsheet - Updated December 2024 . Available at : https :// www . pbs . gov . au / publication / factsheets / covid-19-treatments / PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-updated-December-2024 . pdf . Accessed January 2025 . 5 . COVID-19 Drug Interactions . University of Liverpool , 2024 . Available at : https :// www . covid19-druginteractions . org / checker . Accessed January 2025 . 6 . Hammond J et al . N Eng J Med . 2022 ; 386:1397 – 1408 .
© 2025 . All rights reserved . Pfi zer Australia Pty Ltd , Sydney , Australia . www . pfi zer . com . au . Medical Information : 1800 675 229 . www . pfi zermedicalinformation . com . au . PP-C1D-AUS-0435 . AWF-2634470 . 02 / 25 .